Skip to content
value.today
Pharmacyclics logo

Pharmacyclics

PCYCUnlisted company
No market cap data
Compare
World rank
—
no current market cap
Revenue
$730 M
For year ending December-2014
Net income
$86 M
11.8% margin
SEC filing
Employees
—

Pharmacyclics in brief

Pharmacyclics is an unlisted company in the Biotechnology industry, based in Sunnyvale, USA. It was founded in 1991. In the year to December 2014 it had sales of $730 M and a net profit of $86 M, about 12 cents of profit for every dollar of sales.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Pharmacyclics

Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies. In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Pharmacyclics timeline

2 events, 1991–1996
  1. 1991
  2. 🏁
    · approximate
    Founded
  3. 1996
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of Pharmacyclics from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Pharmacyclics

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 26 May 2015 (Form 8-K).

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
—
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
11.8%
Operating margin
16.8%
Return on equity
10.4%
Liabilities / assets
21.8%
Revenue growth
+180.5%
R&D / revenue
23.6%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2010: revenue $9M, net income $-15M$9MFY10Fiscal year ending Jun 2011: revenue $8M, net income $-35M$8MFY11Fiscal year ending Jun 2012: revenue $82M, net income $12M$82MFY12Fiscal year ending Dec 2013: revenue $260M, net income $67M$260MFY13Fiscal year ending Dec 2014: revenue $730M, net income $86M$730MFY14
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2014$730M+180.5%$122M$86M11.8%
Dec 2013$260M+217.3%$98M$67M25.8%
Jun 2012$82M+896.2%$12M$12M14.6%
Jun 2011$8M-11.6%$-35M$-35M-427.7%
Jun 2010$9M—$-16M$-15M-161.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2014$184M$14M$170M$1.10—
Dec 2013$89M$18M$70M$0.87—
Jun 2012$86M$3M$83M$0.17—
Jun 2011$-22M$1M$-23M$-0.59—
Jun 2010$-15M$0M$-16M$-0.31—

SEC filings

Official filings of Pharmacyclics with the US Securities and Exchange Commission.

Annual results

Revenue
$730 M
Operating income
$122 M
Net income
$86 M

For year ending December-2014 · source: SEC filing

Balance sheet

Total assets
$1.1 B
Total liabilities
$231 M
Total equity
$829 M

As of December-2014

Insider trading at Pharmacyclics#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
43
since
Pharmacyclics: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David Duane SmithDirectorTender in a change of control-3,000$261.25$784 K0Form 4
filed Robert F. BoothDirectorDisposal to the company-10,000$261.25$2.6 M0Form 4
filed Richard Van Den BroekDirectorTender in a change of controlindirect-29,610$261.25$7.7 M0Form 4
filed Eric H. HalvorsonDirectorTender in a change of control-1,000$261.25$261 K0Form 4
filed Heow TanChief Quality&Tech OperationsTender in a change of control-11,721$261.25$3.1 M0Form 4
filed Maky ZanganehChief Operating OfficerDisposal to the company-15,000$261.25$3.9 M351,293Form 4
filed Shawn TomaselloChief Commercial OfficerDisposal to the company-50,000$261.25$13.1 M7,302Form 4
filed Manmeet Singh SoniChief Financial OfficerDisposal to the company-54,000$261.25$14.1 M873Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Pharmacyclics scorecard#

Passes 10 of the 12 checks that could be worked out: strongest in growth (4 of 4), weakest in profitability (3 of 5). Fiscal year 2014.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth4 of 4
    • ✓Revenue grew in the newest year180.5%Revenue up 180.5% in fiscal 2014.
    • ✓Revenue up more than 5% a year over three years345.9%345.9% a year over the three years to fiscal 2014.
    • ✓Faster growth over three years than its peers' median345.9%345.9% a year against Biotechnology's median of 12.9% (181 companies).
    • ✓Earnings per share grew in the newest year1.10 vs 0.87Diluted EPS 1.10 in fiscal 2014 against 0.87 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability3 of 5
    • ✓Profitable in the newest year$86 MNet income $86 M in fiscal 2014.
    • ✗Profitable in each of the last five years3 of 5Profitable in 3 of the five years to fiscal 2014.
    • ✓Operating margin above its peers' median16.8%16.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%11.8%11.8% in fiscal 2014.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier16.8%16.8% in fiscal 2014 against -429.8% in 2011.
  • Financial health2 of 2
    • ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.23 at the end of fiscal 2014.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2014.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.4%Diluted shares up 1.4% in fiscal 2014.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Pharmacyclics: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Pharmacyclics: statements by fiscal year
PeriodTrendFY 2014to Dec 31, 2014FY 2013to Dec 31, 2013FY 2012to Jun 30, 2012FY 2011to Jun 30, 2011FY 2010to Jun 30, 2010
Income statement
Revenue730260828.29.3
Cost of revenue403.500—
Research and development17285553417
Selling, general and administrative16874r169.1—
General and administrative——169.17.6
Operating expenses——704425
Total costs and expenses6071627044—
Operating income1229812−35−16
Interest and finance income——0.20.20.1
Other non-operating income (expense)−0.4−0.1−0.00.0−0.0
Income before tax1229812−35−16
Income tax36310.00−0.6
Net income attributable to shareholders866712−35−15
Earnings per share, basic1.140.920.17-0.59-0.31
Earnings per share, diluted1.100.870.17-0.59-0.31
Shares, weighted average (basic)7573696048
Shares, weighted average (diluted)7877736048
Balance sheet
Cash and cash equivalents8456241988851
Receivables64115.9r0.0r—
Inventory3413———
Other current assets219.33.9r2.3r—
Current assets1,016741213115—
Property, plant and equipment32253.81.3—
Other intangible assets8.70———
Total assets1,060769219116—
Accounts payable7.34.02.6r0.9r—
Current liabilities194881914—
Total liabilities2311418715—
Retained earnings−130−217−401−413—
Shareholders' equity82962813210267
Total liabilities and equity1,060769219116—
Shares outstanding76746968r—
Cash-flow statement
Depreciation and amortization3.92.2r0.6r0.30.2
Share-based compensation54509.97.83.2
Cash from operating activities1848986−22−15
Capital expenditure−14−18−3.0−1.2−0.2
Intangible assets bought−9.300——
Cash from investing activities−23−2016−3.7−22
Shares issued0201−0.65773
Cash from financing activities612488.26274
Change in cash2213171103737
Report10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2015. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Pharmacyclics#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 6 · Material agreement 3 · Agreement ended 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 1 · Results announced 6

Pharmacyclics: events reported to the SEC
FiledWhat happenedFiling
Taken over and delistedChange in controlAcquisition or sale completedShareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Material agreement8-K
Directors and officersMaterial agreementBylaws or fiscal year changed8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Agreement ended8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officersMaterial agreementShareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of May 26, 2015

FDA drug approvals: Pharmacyclics#

5 approved applications held, 1 of them new molecular entities; 0 approvals and 2 new uses in 2023.

Approvals held
5
New molecular entities
1
New uses approved
24
efficacy supplements
Generics
0
5 new drugs, 0 biologics
Pharmacyclics: latest FDA approvals
ApprovedDrugKind
2023-05-18Imbruvicanew useIbrutinib · NDA205552 (SUPPL-40)New drug (NDA)
2023-05-18Imbruvicanew useIbrutinib · NDA210563 (SUPPL-17)New drug (NDA)
2022-08-24Imbruvicanew useIbrutinib · NDA205552 (SUPPL-38)New drug (NDA)
2022-08-24Imbruvicanew useIbrutinib · NDA205552 (SUPPL-36)New drug (NDA)
2022-08-24Imbruvicanew useIbrutinib · NDA205552 (SUPPL-37)New drug (NDA)
2022-08-24Imbruvicanew useIbrutinib · NDA210563 (SUPPL-14)New drug (NDA)
2022-08-24Imbruvicanew useIbrutinib · NDA210563 (SUPPL-12)New drug (NDA)
2022-08-24Imbruvicanew useIbrutinib · NDA210563 (SUPPL-13)New drug (NDA)
2022-08-24ImbruvicaIbrutinib · NDA217003New drug (NDA)
2020-12-18Imbruvicanew useIbrutinib · NDA205552 (SUPPL-32)New drug (NDA)
2020-12-18Imbruvicanew useIbrutinib · NDA210563 (SUPPL-9)New drug (NDA)
2020-04-21Imbruvicanew useIbrutinib · NDA205552 (SUPPL-30)New drug (NDA)
2020-04-21Imbruvicanew useIbrutinib · NDA210563 (SUPPL-6)New drug (NDA)
2019-01-25Imbruvicanew useIbrutinib · NDA205552 (SUPPL-26)New drug (NDA)
2019-01-25Imbruvicanew useIbrutinib · NDA210563 (SUPPL-2)New drug (NDA)
2018-08-24Imbruvicanew useIbrutinib · NDA205552 (SUPPL-24)New drug (NDA)
2018-08-24Imbruvicanew useIbrutinib · NDA210563 (SUPPL-1)New drug (NDA)
2018-02-16ImbruvicaIbrutinib · NDA210563New drug (NDA)
2018-02-16ImbruvicaIbrutinib · NDA210563New drug (NDA)
2017-12-20Imbruvicanew useIbrutinib · NDA205552 (SUPPL-20)New drug (NDA)
2017-08-02Imbruvicanew useIbrutinib · NDA205552 (SUPPL-17)New drug (NDA)
2017-01-18Imbruvicanew useIbrutinib · NDA205552 (SUPPL-16)New drug (NDA)
2016-05-06Imbruvicanew useIbrutinib · NDA205552 (SUPPL-10)New drug (NDA)
2016-05-06Imbruvicanew useIbrutinib · NDA205552 (SUPPL-13)New drug (NDA)
2016-03-04Imbruvicanew useIbrutinib · NDA205552 (SUPPL-7)New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (PHARMACYCLICS LLC), so they follow acquisitions

Layoffs at Pharmacyclics#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2008–2008
Latest
—
2008-02-28
Pharmacyclics: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2008············—
Pharmacyclics: latest layoffs
AnnouncedPeopleKindWhereSource
40% of workforceRestructuring planSEC 8-K“As a result of the corporate realignment, which is expected to be complete by March 31, 2008, the company will reduce its staff by approximately 40%.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Pharmacyclics compares in Biotechnology

  • Revenue$730 M · higher than 90% of 647
  • Net margin11.8% · higher than 79% of 408
  • Revenue growth180.5% · higher than 88% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Pharmacyclics🇺🇸——11.8%+180.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2014
Balance sheet:
As of December-2014
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, Wikipedia, Wikimedia Commons, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Pharmacyclics? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Pharmacyclics's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Pharmacyclics? Suggest a correction